A significant milestone in the treatment of dialysis patients worldwide has been reached with the successful completion of the first commercial procedure utilizing Phraxis, Inc., a leader in vascular access innovation. The landmark treatment was carried out at Spartanburg Regional Medical Center in Spartanburg, South Carolina, by vascular access surgeon Dr. Ari Kramer, one of the device’s early clinical proponents.
The leadership team at Phraxis, alongside the surgical professionals at Spartanburg Regional, celebrated this groundbreaking event, which signals the beginning of U.S. commercialization for EndoForce™. This device is engineered to standardize the creation of dialysis vascular access, offering a fresh, innovative approach to a crucial part of patient care.
EndoForce™ recently received approval from the U.S. Food and Drug Administration (FDA) as the first device of its type created to streamline vascular access procedures by replacing traditional hand-sewn sutures with a precisely engineered, reproducible connector. Designed for compatibility with all PTFE grafts, the device underwent extensive evaluation in a pivotal clinical trial, confirming its safety and efficiency.
“Every choice made in the operating room ultimately focuses on the patient,” said Dr. Ari Kramer of Spartanburg Regional Medical Center. “EndoForce® is a new instrument that improves the efficiency and predictability of graft-to-vein connections. Launching the first commercial case here represents a meaningful advancement for the dialysis community.”
Dr. Alex Yevzlin, Founder and Chief Executive Officer of Phraxis, Inc., reflected on the accomplishment, noting, “This milestone represents over a decade of persistent innovation, close collaboration with world-class surgeons, and dedication to improving patient outcomes. We are thrilled to see EndoForce™ make its clinical debut, where it can begin delivering real impact.”
Geoffrey Beecher, Chief Commercial Officer of Phraxis, Inc., added, “Today is more than the completion of a first case—it marks the dawn of a new era in vascular access surgery. EndoForceTM is made to deliver on the promise that dialysis patients deserve reliable, consistent solutions.”
Following the successful Spartanburg case, Phraxis will work with leading vascular surgeons and health systems to broaden availability nationwide, with additional clinical sites expected to begin procedures in the near future.
